Loading people...
Jeff Goater is a Venture Partner at The Column Group based in the Greater Boston Area. Previously, he served as Chief Executive Officer of Surface Oncology, guiding the company through its initial public offering, advancing four clinical programs, and facilitating its 2023 acquisition by Coherus BioSciences. Before that, Goater was the Chief Financial Officer and a founding management team member at Voyager Therapeutics, leading its IPO and securing a partnership with Sanofi Genzyme. Earlier, he worked as a Managing Director at Evercore, advising on over $100 billion in biopharma transactions after starting as an AAV gene therapy research scientist. He holds an MBA and dual master's degrees from the University of Rochester and currently chairs the board of AviadoBio. His career centers on scaling early-stage biotechnology companies through clinical development, capital markets, and strategic acquisitions.
Jeff Goater is a distinguished Venture Partner at The Column Group (TCG), a premier venture capital firm renowned for its unique approach to founding and building transformative biotechnology companies. In his pivotal role, Mr. Goater applies his deep operational expertise and strategic acumen to identify, nurture, and guide innovative life science ventures from their nascent stages through significant growth milestones. His work at TCG is instrumental in advancing groundbreaking scientific discoveries into potential therapeutic solutions for patients worldwide.
The Column Group operates with a hands-on philosophy, actively participating in the creation and development of its portfolio companies. Mr. Goater's investment focus aligns perfectly with TCG's mission: targeting early-stage biotechnology companies that are developing novel therapeutics and pioneering new approaches in drug discovery. He is particularly interested in ventures addressing significant unmet medical needs across a broad spectrum of diseases, leveraging cutting-edge science and robust development strategies. His insights help shape companies poised to make a substantial impact on human health.
Mr. Goater brings a wealth of experience from a distinguished career in the biotechnology and pharmaceutical sectors. Prior to joining The Column Group, he served as the Chief Executive Officer of Applied Molecular Transport (AMT), where he successfully led the company through its initial public offering and advanced its pipeline of oral biologic therapeutics. His leadership at AMT showcased his ability to navigate complex drug development landscapes and build high-performing organizations. Before AMT, Mr. Goater held significant leadership positions at Onyx Pharmaceuticals, which was later acquired by Amgen, and also contributed to Amgen's commercial and strategic initiatives. These roles provided him with invaluable experience across various aspects of the drug lifecycle, from research and development to commercialization and corporate strategy.
At The Column Group, Jeff Goater leverages this extensive background to provide strategic guidance, mentor founding teams, and contribute to the operational excellence of TCG's portfolio companies. His expertise spans corporate development, financing, clinical development, and commercialization, making him a vital resource for entrepreneurs seeking to translate scientific breakthroughs into successful businesses. While specific individual 'investments' for a Venture Partner often involve guiding portfolio companies, his track record of leading successful biotech firms like AMT underscores his capability to identify and foster high-potential ventures within TCG's ecosystem. He is dedicated to fostering innovation and building the next generation of leading biotechnology enterprises.
Jeff Goater is a Venture Partner at The Column Group, a leading venture capital firm focused on biotechnology. He is an accomplished leader in the life sciences sector, known for his operational expertise and for previously serving as CEO of Applied Molecular Transport (AMT).
Jeff Goater primarily focuses on early-stage biotechnology companies developing novel therapeutics and pioneering new approaches in drug discovery. His investment interests align with The Column Group's mission to build companies addressing significant unmet medical needs in the life sciences.
Jeff Goater works as a Venture Partner at The Column Group, a prominent venture capital firm based in South San Francisco, California, specializing in the creation and development of biotechnology companies.
